Search 

Respinova has developed a new device for the treatment of COPD a group of progressive, debilitating respiratory conditions, including emphysema and chronic bronchitis. COPD is the third leading cause of death. Worldwide there are over 350 million with 50 million in China.
Respinova’s Pulsehaler™ technology is the first and only treatment to directly re-open the collapsed small airways of COPD patients, thereby reducing breathlessness and improving patient’s ability to walk. The technology was clinically proven in a clinical study, and published in the peer reviewed Journal of COPD. Our technology is protected by 6 patent families, with 15 issued patents and many additional pending patents.
Respinova’s technology pipeline also includes devices for improving delivery of inhaled drugs. This technology was clinically proven to deliver drugs more than 200% better than traditional nebulizers, with significant improvements in lung function. We have begun initial discussions with Pharma companies to partner in the development of Best-in-Class inhaled therapies, including COPD, Cystic Fibrosis, Asthma, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension.

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!

Pharma and diagnostics

Rongsheng focuses on biotechnology companies and biomedical funds worldwide, especially innovative drugs and breakthrough therapies.

1994年成立上海市国资委直属投资公司

We are a group of angels selecting top companies to invest.

Sangel Capital provides venture capital and business finance to support high-tech enterprises in China and US. The firm seeks to invest in innovative startups in sectors including biopharma, diagnostics, medical devices, and biotech.
Sangel Capital was founded in 2010 and is based in Shenzhen, Beijing with additional offices in Suzhou and Chicago.

Big Pharma